Trial Profile
CARFILZOMIB IN COMBINATION WITH BENDAMUSTINE AND DEXAMETHASONE IN REFRACTORY OR RELAPSED MULTIPLE MYELOMA - A MULTICENTER PHASE IB/II TRIAL OF THE EUROPEAN MYELOMA NETWORK TRIALIST GROUP (EMNTG)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Bendamustine; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- 19 Feb 2024 Status changed from active, no longer recruiting to completed.
- 26 Jul 2022 Planned End Date changed from 1 Apr 2022 to 1 Sep 2022.
- 28 Jun 2021 Initially, lymphopenia was considered a Dose Limiting Toxicity, but this was amended after phase 1, and mandatory infectious prophylaxis was incorporated into the protocol